AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 282 min read$AVTR

Avantor Q3 Sales Rise 4.6% to $1.70 Billion; Adjusted EPS $0.22

Avantor reported Q3 2026 net sales of $1.70 billion, up 4.6% YoY, with organic growth of 5.2%. Adjusted EPS was $0.22. The company raised its full-year guidance for organic revenue growth, adjusted EPS, and free cash flow. Net income was $203.4 million, reversing a prior-year loss of $711.8 million.

Original reporting
tradingview.com
Published Oct 28, 2026, 10:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Avantor Q3 Sales Rise 4.6% to $1.70 Billion; Adjusted EPS $0.22 — source image
Source · tradingview.com
Decision brief

The 30-second read

$AVTRBullishHigh
01

Why it matters

The upward revision signals stronger demand for Avantor's bioscience and medtech products, likely supporting a bullish move.

02

Market read

Fresh earnings and guidance raise provide a clear catalyst for AVTR traders.

03

What to watch

Potential macro headwinds or supply chain constraints could limit upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Avantor's Q3 earnings beat expectations and the company lifted its 2026 outlook for organic revenue growth, adjusted EPS, and free cash flow.

Company-level read

Ticker impact

$AVTRBullishHigh confidence
Context

Avantor reported Q3 2026 results with sales up 4.6% YoY and raised full-year organic revenue growth and EPS guidance.

Expected impact

potential upside as the market prices in higher revenue and EPS outlook

Evidence & confidence

The earnings beat and upward guidance are fresh, material information that can move the stock immediately.

Market effects

Sector

Positive for life-sciences and specialty chemicals suppliers.

Regional

May boost US biotech and industrial supply chain sentiment.

Global

Limited to investors tracking specialty chemicals and biotech supply chains.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, the stock could face a pullback.

Key entities

  • Company
    Avantor, Inc.

    Specialty chemicals and life-sciences supplier.

Read at source← All news

StoryAvantor posts Q3 profit, lifts FY 2026 revenue and EPS guidance

Also covered by

5 outlets

Related articles

OCT 28
$AVTRMedAI 8/10

Avantor beats Q3 estimates but shares slip on guidance

Avantor Inc. (NYSE: AVTR) reported Q3 adjusted EPS of $0.22, beating estimates by $0.01, with revenue of $1.70B, up 4.6% YoY. Shares fell 2.6% as guidance matched expectations. The company raised its full-year organic revenue growth and free cash flow outlooks. Organic revenue grew 5.2% YoY, with segments showing varied performance.

investing.com2 min
OCT 28
$AVTRMedAI 8/10

Avantor (NYSE:AVTR) reports upbeat Q3 2026

Avantor (AVTR) reported Q3 2026 revenue of $1.70B, beating estimates by 3.4% YoY. Adjusted EPS was $0.22, a 5.6% beat. Adjusted EBITDA was $256.9M, a 2.6% beat. Management raised full-year EPS guidance to $0.82. Operating margin improved to 8.2%, while free cash flow margin decreased to 9.2%. Organic revenue grew 5.2% YoY.

finance.yahoo.com2 min
OCT 28
$AVTRHigh

Avantor® Reports Third Quarter 2026 Results

Avantor, Inc. (AVTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Avantor® Reports Third Quarter 2026 Results • Net sales of $1,698.3 million; increase of 4.6%; organic increase of 5.2% • Diluted GAAP EPS of $0.30; adjusted EPS of $0.22 • Raised FY 2026 organic revenue growth, adjusted EPS and free cash flow guidance RADNOR, Pa. –

SEC EDGAR 8-K2 min